EUVIMEDEUVIMED entdecken
Open Access

Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia

Guru Subramanian Guru Murthy iD, Brent R Logan, Stephanie Bo-Subait, Amer Beitinjaneh, Steven Devine iD, Nosha Farhadfar, Lohith Gowda, Shahrukh Hashmi, Hillard Lazarus, Sunita Nathan, Akshay Sharma, Jean A Yared und 6 weitere

American Journal of Hematology · 2023-04 · 98 (4) · 608-619

DOI: 10.1002/ajh.26834 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Hematology, online erschienen am 16.01.2023. Verfasst von Guru Subramanian Guru Murthy und 17 weiteren Autor:innen. Beteiligte Einrichtung: CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, …. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Graft vs Host Disease. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS, HRSA HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic hematopoietic cell transplantation (allo‐HCT) is a potentially curative treatment for acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL). While many factors influence the outcomes of allo‐HCT, the independent impact of donor–recipient ABO mismatching remains unclear. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) database, we identified patients aged ≥18 years with AML or ALL who underwent allo‐HCT between 2008 and 2018. Our objectives were to analyze the outcomes of allo‐HCT based on the donor–recipient ABO status (match, minor mismatch, major mismatch, bidirectional mismatch). Among 4946 eligible patients, 2741 patients (55.4%) were ABO matched, 1030 patients (20.8%) had a minor ABO mismatch, 899 patients (18.1%) had a major ABO mismatch, and 276 patients (5.6%) had a bidirectional ABO mismatch. In multivariable analyses, compared to ABO matched allo‐HCT, the presence of a major ABO mismatch was associated with worse overall survival (HR 1.16, 95% CI 1.05–1.29; p = 0.005), inferior platelet engraftment (HR 0.83, 95% CI 0.77–0.90; p < 0.001), and higher primary graft failure (HR 1.60, 95% CI 1.12–2.30, p = 0.01). Relapse, acute graft versus host disease (GVHD) grades III‐IV and chronic GVHD were not significantly associated with ABO status. While donor age was not significantly associated with outcomes, older recipient age was associated with worse survival and non‐relapse mortality. Our study demonstrates that donor–recipient ABO status is independently associated with survival and other post‐transplantation outcomes in acute leukemia. This underscores the importance of considering the ABO status in donor selection algorithms and its impact in acute leukemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationLeukemia, Myeloid, AcutePrecursor Cell Lymphoblastic Leukemia-LymphomaGraft vs Host DiseaseHumansAdolescentAdultBone Marrow TransplantationBone MarrowAcute DiseaseRetrospective StudiesTransplantation Conditioning

Autor:innen und Institutionen

  • CIBMTR® (Center for International Blood and Marrow Transplant Research), Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • CIBMTR® (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, Minnesota, USA.
  • Division of Transplantation and Cellular Therapy, University of Miami Hospital and Clinics, Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
  • Division of Hematology/Oncology, University of Florida College of Medicine, Gainesville, Florida, USA.
  • Yale Cancer Center and Yale School of Medicine, New Haven, Connecticut, USA.

ORCID-Profile: Guru Subramanian Guru Murthy, Steven Devine

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS
  • HRSA HHS
  • Health Resources and Services Administration
  • National Cancer Institute
  • National Heart, Lung, and Blood Institute
  • National Institute of Allergy and Infectious Diseases
  • Office of Naval Research

Zitieren

APA

Guru Murthy, G. S., Logan, B. R., Bo-Subait, S., Beitinjaneh, A., Devine, S., Farhadfar, N., Gowda, L., Hashmi, S., Lazarus, H., Nathan, S., Sharma, A., Yared, J. A., Stefanski, H. E., Pulsipher, M. A., Hsu, J. W., Switzer, G. E., Panch, S. R., & Shaw, B. E. (2023). Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. American Journal of Hematology, 98(4), 608-619. https://doi.org/10.1002/ajh.26834

Vancouver

Guru Murthy GS, Logan BR, Bo-Subait S, Beitinjaneh A, Devine S, Farhadfar N, et al. Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia. American Journal of Hematology. 2023;98(4):608-619. doi:10.1002/ajh.26834

BibTeX
@article{GuruMurthy2023,
  author = {Guru Murthy, Guru Subramanian and Logan, Brent R and Bo-Subait, Stephanie and Beitinjaneh, Amer and Devine, Steven and Farhadfar, Nosha and Gowda, Lohith and Hashmi, Shahrukh and Lazarus, Hillard and Nathan, Sunita and Sharma, Akshay and Yared, Jean A and Stefanski, Heather E and Pulsipher, Michael A and Hsu, Jack W and Switzer, Galen E and Panch, Sandhya R and Shaw, Bronwen E},
  title = {Association of ABO mismatch with the outcomes of allogeneic hematopoietic cell transplantation for acute leukemia},
  journal = {American Journal of Hematology},
  year = {2023},
  volume = {98},
  number = {4},
  pages = {608--619},
  doi = {10.1002/ajh.26834}
}
Kostenlos starten →